HSBC has initiated coverage on Krishna Institute of Medical Sciences (KIMS) with a “Buy” rating and a target price of ₹3,300 per share, suggesting a 20.7% upside from the stock’s closing price of ₹2,734 on September 12. The initiation reflects HSBC’s confidence in KIMS’ growth prospects and operational efficiency.
KIMS is recognized for its affordable healthcare services and robust operational execution in its core markets. HSBC forecasts a compound annual growth rate (CAGR) of approximately 26% in profit after tax (PAT) over FY24-27, driven by bed additions and an improving service mix. Key factors to watch include the expansion of new hospitals in Mumbai, Nashik, and Bengaluru, which are expected to significantly contribute to the company’s growth trajectory.
